Market-neutral funds often short liquid biotech stocks that lack near-term binary events to finance their long positions. However, this year's M&A environment has seen several of these companies acquired at a premium, making this shorting strategy particularly challenging.

A common Wall Street strategy is to 'short the launch'—betting against a biotech company's stock when it tries to commercialize its own drug. This reflects a systemic belief that startups lack the commercial 'muscle' to succeed, forcing them into a cycle of being acquired by big pharma rather than building into standalone giants.

High-conviction shorting in biotech is dangerous due to promotional news and massive upside catalysts. A quantitative approach, diversifying shorts across many names with negative signals, provides better risk-adjusted returns than a few concentrated, "fraud" bets that have burned fundamental managers.

While the XBI is up significantly, this is driven by under-owned or shorted stocks like Moderna. Meanwhile, the companies most specialist biotech funds actually own are "getting hammered," creating a disconnect between the index's performance and investors' actual portfolio returns.

Although the XBI index gained over 20%, specialized biotech fund managers experienced acute underperformance. The rally was driven by tech or AI stocks that biotech specialists rarely hold, while crowded long positions lagged and heavily shorted names rebounded sharply against fund positions.

Early-stage biotech companies are vulnerable to short selling in public markets because their experiments run for 12-24 months, creating long periods without news flow. With no catalysts to drive buying ("no bid"), hedge funds can short the stocks until data is released, highlighting a structural disadvantage of being public too early.

In a capital-constrained market, positive clinical data can trigger a stock drop for biotechs with insufficient cash. The scientific success highlights an immediate need for a highly dilutive capital raise, which investors price in instantly. Having over two years of cash is now critical to realizing value.

Market dynamics, like investor fixation on AI or predatory short-selling, pose a greater risk to biotech firms than clinical trial results. A company can have a breakthrough drug but still fail if its stock—its funding currency—is ignored or attacked by Wall Street.

Moderna's positive trial results drove a stock surge fueled by generalist investors. This frustrated many specialist biotech funds who were short the stock or didn't hold it, causing them to underperform their benchmark and complain about "unsophisticated" capital.